Intravascular large B-cell lymphoma: Remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy (original) (raw)
Related papers
Intravascular Large B-cell Lymphoma: A Case Serie
2020
Scan to discover online One of the rare variants of extranodal large B-cell lymphoma is intravascular large B-cell lymphoma (IVLBCL). Characteristics of IVLBCL include intraluminal selective proliferation of atypical lymphoid cells in small to medium-sized vessels. The etiologic of IVLBCL is unknown, but due to the growth pattern of this tumor, it is speculated that IVLBCL is caused by a defect in homing receptor of tumor cells. IVLBCL can involve any organ but central nervous system, lungs, and skin are the most involved sites. IVLBCL does not usually involve lymph nodes. IVLBCL mainly occurs in the middle aged to elderly population with a slight male predominance. Generally, IVLBCL is aggressive and rapidly fatal if left untreated.
Journal of Clinical Oncology, 2008
Purpose To evaluate the safety and efficacy of rituximab-containing chemotherapies for intravascular large B-cell lymphoma (IVLBCL). Patients and Methods We retrospectively analyzed 106 patients (59 men, 47 women) with IVLBCL who received chemotherapy either with rituximab (R-chemotherapy, n = 49) or without rituximab (chemotherapy, n = 57) between 1994 and 2007 in Japan. The median patient age was 67 years (range, 34 to 84 years). The International Prognostic Index was high-intermediate/high in 97% of patients. Results The complete response rate was higher for patients in the R-chemotherapy group (82%) than for those in the chemotherapy group (51%; P = .001). The median duration of follow-up for surviving patients was 18 months (range, 1 to 95 months). Progression-free survival (PFS) and overall survival (OS) rates at 2 years after diagnosis were significantly higher for patients in the R-chemotherapy group (PFS, 56%; OS, 66%) than for patients in the chemotherapy group (PFS, 27% w...
The challenging diagnosis of intravascular large B-cell lymphoma
2021
Livedo reticularis (LR) is a net-like cyanotic skin pattern resulting from cutaneous blood flow disturbance associated with several medical conditions. The authors present a case of a 77-year-old woman with a history of asthenia over one year, admitted to the hospital with sepsis by pneumonia. During her hospitalization, she developed a livedoid rash, and skin biopsy revealed infiltrates of atypical mononuclear cells causing capillary lumen obstruction. Intravascular large B-cell lymphoma was suspected and confirmed by bone marrow study. This case highlights the importance of being aware of different medical conditions associated with LR and the atypical presentation of a lymphoproliferative disorder. Correspondence: Ana Filipa Coroado da Silva Ferreira, Internal Medicine Department, Centro Hospitalar do Baixo Vouga, Aveiro, Av. Artur Ravara, 3810-501 Aveiro, Portugal. Tel.: 234.378.300. E-mail: afilipa.csferreira@gmail.com
Intravascular large B cell lymphoma
IP innovative publication pvt. ltd, 2019
Intravascular Large B Cell Lymphoma (IVLBCL) is a unique subset of Diffuse Large B cell lymphoma. No randomised trials have been done on IVBCL till date as this a very rare type of Non Hodgkin Lymphoma. The clinical presentations are varied. The awareness about the disease and a high index of suspicion are required to diagnose a case of IVBCL. We report a case of 71 year old lady who was extensively investigated for fever of unknown origin, and finally one vessel in the bone marrow biopsy showed Intravascular Large B Cells.
Clinical Lymphoma, 2005
Intravascular large B-cell lymphoma (ILBCL) is a rare subtype of diffuse large B-cell lymphoma (as currently recognized by the World Health Organization classification) and is characterized by proliferation of mature B-cells within the lumina of small and medium vessels. We report on a 66-year-old man who presented with a fever of undetermined origin, a splenomegaly, and an elevated lactate dehydrogenase level. The diagnosis of ILBCL was established by a bone marrow biopsy that showed CD20 + tumor cells confined within the lumina of sinuses. A karyotypic analysis obtained from the bone marrow aspirate showed a hypotetraploid clone. Magnetic resonance imaging of the brain revealed multiple high-signal areas in the periventricular white matter above the tentorium. Focal dural enhancement (pachymeningitis) close to the medium third of the superior sagittal sinus was also observed and was related to a partial superior sagittal sinus thrombosis as confirmed by venous magnetic resonance angiography. After 8 courses of a CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) plus rituximab regimen, normalization of the superior sagittal sinus and of the bone marrow was obtained. With a follow-up of 15 months, the patient is still considered in complete remission. This observation highlights an unusual vascular aspect of ILBCL and the efficacy of the current standard treatment for this age group (CHOP/rituximab) in this particularly aggressive lymphoma subtype.